2013 ACR/ARHP Annual Meeting
October 25-30, 2013. San Diego, CA.
- 2013 Rheumatology Research Foundation Edmond L. Dubois, MD Memorial Lectureship
- ACR Late-Breaking Abstract Oral Session
- ACR Late-Breaking Abstract Poster Session
- ACR Plenary Session I: Discovery 2013
- ACR Plenary Session II: Discovery 2013
- ACR Plenary Session III: Discovery 2013
- ACR/ARHP Combined Epidemiology Abstract Session
- ACR/ARHP Combined Pediatrics Abstract Session
- ACR/ARHP Combined Rehabilitation Abstract Session
- ARHP Education/Community Programs
- ARHP Epidemiology and Public Health
- ARHP Health Services Research
- ARHP Imaging of Rheumatic Disease: Research Methodology
- ARHP Noteworthy Abstracts
- ARHP Orthopedics, Low Back Pain and Rehabilitation: Rehabilitation Sciences
- ARHP Osteoarthritis - Clinical Aspects: Psychology/Social Sciences
- ARHP Pediatrics
- ARHP Rheumatoid Arthritis - Clinical Aspects: Clinical Practice/Patient Care
- Antiphospholipid Syndrome
- Antiphospholipid Syndrome: Clinical Manifestations and New Biomarkers in Antiphospholipid Syndrome
- B cell Function and Targeting in Systemic Lupus Erythematosus
- B cells in Human and Animal Arthritis
- B cells in Systemic Lupus Erythematosus
- Biology and Pathology of Bone and Joint (Bone and Arthritis)
- Biology and Pathology of Bone and Joint (Cartilage and Osteoarthritis)
- Biology and Pathology of Bone and Joint I: Cartilage Biology and Osteoarthritis
- Biology and Pathology of Bone and Joint II: Osteoclast Biology and Arthritis
- Clinical Practice/Patient Care
- Cytokines, Mediators, Cell-cell Adhesion, Cell Trafficking and Angiogenesis I
- Cytokines, Mediators, Cell-cell Adhesion, Cell Trafficking and Angiogenesis I: Identifying Novel Factors that Facilitate Neovascularization and Cell Trafficking
- Cytokines, Mediators, Cell-cell Adhesion, Cell Trafficking and Angiogenesis II
- Cytokines, Mediators, Cell-cell Adhesion, Cell Trafficking and Angiogenesis II: Mechanisms that contribute to autoimmune inflammation
- Education/Community Programs
- Epidemiology and Health Services I
- Epidemiology and Health Services II & III
- Epidemiology and Health Services Research I: Comorbidities in Rheumatic Diseases
- Epidemiology and Health Services Research II: Epidemiology in Systemic Lupus Erythematosus and Rheumatoid Arthritis
- Epidemiology and Health Services Research III: Healthcare Costs and Mortality in Rheumatic Disease
- Epidemiology and Health Services Research VI: Risk Factors in Rheumatic Disease Susceptibility
- Epidemiology and Public Health
- Fibromyalgia, Soft Tissue Disorders and Pain I
- Fibromyalgia, Soft Tissue Disorders and Pain II
- Fibromyalgia, Soft Tissue Disorders and Pain: Diagnosis and Disease Epidemiology
- Fibromyalgia, Soft Tissue Disorders and Pain: Treatment and Outcome Assessment
- Genetics and Genomics of Rheumatic Disease I
- Genetics and Genomics of Rheumatic Disease II
- Health Services Research, Quality Measures and Quality of Care - Innovations in Health Care Delivery
- Health Services Research, Quality Measures and Quality of Care - Pediatrics, Immunization and Choosing Wisely
- Health Services Research, Quality Measures and Quality of Care-Rheumatoid Arthritis
- Imaging in Pediatric Arthritis, Spondyloarthritis and Osteoarthritis
- Imaging in Rheumatoid Arthritis
- Imaging of Rheumatic Diseases I: Imaging in Gout, Pediatric, Soft and Connective Tissue Diseases
- Imaging of Rheumatic Diseases II: Imaging in Spondyloarthritis and Osteoarthritis
- Imaging of Rheumatic Diseases: Imaging in Vascular and Extra-articular
- Infection Related Rheumatic Diseases
- Innate Immunity and Rheumatic Disease
- Medical Education
- Metabolic and Crystal Arthropathies I
- Metabolic and Crystal Arthropathies II
- Miscellaneous Rheumatic Diseases
- Miscellaneous Rheumatic and Inflammatory Diseases I: Autoinflammatory Syndromes
- Miscellaneous Rheumatic and Inflammatory Diseases II: Autoinflammatory Syndromes
- Miscellaneous Rheumatic and Inflammatory Diseases II: Miscellaneous Rheumatic Diseases
- Muscle Biology, Myositis and Myopathies I: Insights into Mechanisms of the Idiopathic Inflammatory Myopathies
- Muscle Biology, Myositis and Myopathies: Advances in the Epidemiology, Immunology and Therapy of Myositis
- Orthopedics, Low Back Pain and Rehabilitation
- Orthopedics, Low Back Pain, Rehabilitation and Mechanisms of Pain in Arthritis
- Osteoarthritis - Clinical Aspects I: Risk Factors for and Sequelae of Osteoarthritis.
- Osteoarthritis - Clinical Aspects II: Symptoms and Therapeutics in Osteoarthritis.
- Osteoarthritis I: Therapeutics in Osteoarthritis
- Osteoarthritis II: Risk Factors and Natural History of Osteoarthritis
- Osteoporosis and Metabolic Bone Disease: Clinical Aspects and Pathogenesis
- Pain - Basic Mechanisms
- Pediatric Rheumatology - Clinical and Therapeutic Aspects I: Juvenile Idiopathic Arthritis
- Pediatric Rheumatology - Clinical and Therapeutic Aspects II: Autoinflammatory Disease and Systemic Juvenile Idiopathic Arthritis
- Pediatric Rheumatology - Clinical and Therapeutic Aspects II: Pediatric Systemic Lupus Erythematosus, Pediatric Vasculitis and Pediatric Myositis
- Pediatric Rheumatology - Clinical and Therapeutic Aspects III: Systemic Lupus Erythematosus and Other Disease Outcomes
- Pediatric Rheumatology - Pathogenesis and Genetics
- Pediatric Rheumatology-Clinical and Therapeutic Aspects III: Juvenile Idiopathic Arthritis and Other Pediatric Rheumatic Diseases
- Pediatric Rheumatology: Clinical and Therapeutic Disease: Juvenile Idiopathic Arthritis
- Psychology/Social Sciences/Pediatrics
- Rehabilitation Sciences
- Research and Health Services
- Rheumatoid Arthritis - Animal Models I
- Rheumatoid Arthritis - Animal Models II
- Rheumatoid Arthritis - Autoantibodies and Citrullinated Proteins
- Rheumatoid Arthritis - Clinical Aspects I: Comorbidities in Rheumatoid Arthritis
- Rheumatoid Arthritis - Clinical Aspects I: Treatment Strategies in Rheumatoid Arthritis
- Rheumatoid Arthritis - Clinical Aspects II: Identifying Rheumatoid Arthritis in At-Risk Populations
- Rheumatoid Arthritis - Clinical Aspects II: Predictors of Disease Course in Rheumatoid Arthritis - Treatment Approaches
- Rheumatoid Arthritis - Clinical Aspects III: Predictors of Disease Course in Rheumatoid Arthritis
- Rheumatoid Arthritis - Clinical Aspects IV: Comorbidities in Rheumatoid Arthritis
- Rheumatoid Arthritis - Clinical Aspects V: Observational Studies in Rheumatoid Arthritis
- Rheumatoid Arthritis - Clinical Aspects VI: Cardiovascular Disease in Rheumatoid Arthritis
- Rheumatoid Arthritis - Clinical Aspects VII: Remission, Flare and Outcome Measures in Rheumatoid Arthritis
- Rheumatoid Arthritis - Human Etiology and Pathogenesis
- Rheumatoid Arthritis - Pathogenetic Pathways
- Rheumatoid Arthritis Treatment - Small Molecules, Biologics and Gene Therapy I
- Rheumatoid Arthritis Treatment - Small Molecules, Biologics and Gene Therapy II
- Rheumatoid Arthritis Treatment - Small Molecules, Biologics and Gene Therapy III
- Rheumatoid Arthritis Treatment - Small Molecules, Biologics and Gene Therapy: Efficacy and Safety of Novel Entities
- Rheumatoid Arthritis Treatment - Small Molecules, Biologics and Gene Therapy: Efficacy of Approved Biologics I
- Rheumatoid Arthritis Treatment - Small Molecules, Biologics and Gene Therapy: Efficacy of Approved Biologics II
- Rheumatoid Arthritis Treatment - Small Molecules, Biologics and Gene Therapy: Novel Treatment Strategies in Rheumatoid Arthritis
- Rheumatoid Arthritis Treatment - Small Molecules, Biologics and Gene Therapy: Safety Issues
- Rheumatoid Arthritis Treatment - Small Molecules, Biologics and Gene Therapy: Safety and Efficacy of Small Molecule Agents
- Rheumatoid Arthritis-Clinical Aspects III: Outcome Measures, Socioeconomy, Screening, Biomarkers in Rheumatoid Arthritis
- Rheumatoid Arthritis: Human Etiology and Pathogenesis II
- Sjögren's Syndrome: Basic Science
- Sjögren's Syndrome: Clinical Advances
- Sjögren's Syndrome: Clinical Aspects
- Sjögren's Syndrome: Pathogenesis
- Spondylarthropathies and Psoriatic Arthritis - Pathogenesis, Etiology
- Spondylarthropathies and Psoriatic Arthritis: Clinical Aspects and Treatment III
- Spondylarthropathies and Psoriatic Arthritis: Clinical Aspects and Treatment: Clinical Features of Spondylarthritis
- Spondylarthropathies and Psoriatic Arthritis: Clinical Aspects and Treatment: Clinical and Imaging Aspects of Axial Spondyloarthritis
- Spondylarthropathies and Psoriatic Arthritis: Clinical Aspects and Treatment: II
- Spondylarthropathies and Psoriatic Arthritis: Clinical Aspects and Treatment: Imaging in Axial Spondylarthropathies: Challenges, Advances
- Spondylarthropathies and Psoriatic Arthritis: Clinical Aspects and Treatment: Psoriatic Arthritis: Clinical Aspects and Treatment I
- Spondylarthropathies and Psoriatic Arthritis: Clinical Aspects and Treatment: Therapeutics and Outcomes in Psoriatic Arthritis
- Spondylarthropathies and Psoriatic Arthritis: Clinical Aspects and Treatment: Therapeutics and Outcomes in Spondyloarthritis
- Spondyloarthropathies and Psoriatic Arthritis: Pathogenesis, Etiology, Animal Models I
- Spondyloarthropathies and Psoriatic Arthritis: Pathogenesis, Etiology, Animal Models II
- Systemic Lupus Erythematosus - Animal Models
- Systemic Lupus Erythematosus - Clinical Aspects I - Renal, Malignancy, Cardiovascular Disease
- Systemic Lupus Erythematosus - Clinical Aspects II: Central Nervous System Manifestations, Therapeutics
- Systemic Lupus Erythematosus - Clinical Aspects and Treatment: Biologic Therapy
- Systemic Lupus Erythematosus - Clinical Aspects and Treatment: Lupus Nephritis and Genetics
- Systemic Lupus Erythematosus - Clinical Aspects: Cardiovascular and Other Complications of Lupus
- Systemic Lupus Erythematosus - Clinical Aspects: Non-biologic Disease-modifying Antirheumatic Drugs
- Systemic Lupus Erythematosus - Clinical Aspects: Pregnancy
- Systemic Lupus Erythematosus - Human Etiology and Pathogenesis I
- Systemic Lupus Erythematosus - Human Etiology and Pathogenesis II
- Systemic Lupus Erythematosus - Human Etiology and Pathogenesis: Mechanisms and Biomarkers
- Systemic Lupus Erythematosus-Clinical Aspects III: Biomarkers, Quality of Life and Disease Indicators, Late Complications
- Systemic Lupus Erythematosus-Human Etiology and Pathogenesis: Genetics and Genomics
- Systemic Sclerosis, Fibrosing Syndromes and Raynaud's I
- Systemic Sclerosis, Fibrosing Syndromes and Raynaud's: Pathogenesis, Animal Models, Genetics: Novel Signaling Pathways Mediating Fibrosis
- Systemic Sclerosis, Fibrosing Syndromes and Raynaud’s-Clinical Aspects and Therapeutics III
- Systemic Sclerosis, Fibrosing Syndromes and Raynaud’s-Pathogenesis, Animal Models and Genetics I: Therapeutic Interventions in Preclinical Animal Models of Scleroderma
- Systemic Sclerosis, Fibrosing Syndromes and Raynaud’s-Pathogenesis, Animal Models and Genetics: Pathogenesis of Systemic Sclerosis
- Systemic Sclerosis, Fibrosing Syndromes, and Raynaud's II
- Systemic Sclerosis, Fibrosing Syndromes, and Raynaud’s - Clinical Aspects and Therapeutics I
- Systemic Sclerosis, Fibrosing Syndromes, and Raynaud’s - Clinical Aspects and Therapeutics II
- T-cell Biology and Targets in Autoimmune Disease
- T-cell Biology and Targets in Autoimmune Disease: Signaling Pathways in T-cell Differentiation
- T-cell Biology in Autoimmune Diseases
- Vasculitis I
- Vasculitis II
- Vasculitis III
